Number of patients | Median follow up time | treatment | Overall survival rate | All grade 3-5 toxicities | |
---|---|---|---|---|---|
9 | 26.5 months | SBRT | 50% (2-year) | 33% | |
125 | 17.4 months | SBRT | 64% (2-year) | 8% | |
34 | 18.4 months | SBRT | 63.2% (2-year) | 3% | |
80 | 47 months | SBRT | 53% (3-year) | 6.4% | |
33 | 48 months | PBT | Not applicable | 0 | |
present study | 20 | 27.5 months | PBT | 73.8% (2-year) | 0 |
Toxicities | Grade 0 | Grade 1 | Grade 2 | Grade 3 - 5 |
---|---|---|---|---|
0 | 18 (90%) | 2 (1 0%) | 0 | |
20 (100%) | 0 | 0 | 0 | |
16 (80%) | 4 (20%) | 0 | 0 | |
15 (75%) | 3 (15%) | 2 (10%) | 0 |
Characteristics | Patients |
---|---|
Age (years) | |
Median (range) | 75 (63–90) |
Gender | |
Male | 17 (85%) |
Female | 3 (15%) |
Performance status | |
0 | 8 (40%) |
1 | 8 (40%) |
2 | 4 (20%) |
Charlson Index | |
0 | 5 (25%) |
1 | 6 (30%) |
2 | 7 (35%) |
3 | 2 (10%) |
Follow-up time (months) | |
Median (range) | 27.5 (12-72) |
Chronic obstructive pulmonary disease | |
Yes | 9 (45%) |
No | 11 (55%) |
T category Numbers correspond to the tumor-node-metastasis system of classification (International Union Against Cancer criteria) |
|
T1 | 4 (20%) |
T2 | 11 (55%) |
T3 | 4 (20%) |
T4 | 1 (5%) |
Stage Numbers correspond to the tumor-node-metastasis system of classification (International Union Against Cancer criteria) |
|
I | 15 (75%) |
II | 4 (20%) |
III | 1 (5%) |
Tumor location | |
Right upper lobe | 7 (35%) |
Right middle lobe | 2 (10%) |
Right lower lobe | 6 (30%) |
Left upper lobe | 3 (15%) |
Left lower lobe | 2 (10%) |
Histopathology | |
Squamous cell carcinoma | 8 (40%) |
Adenocarcinoma | 5 (25%) |
Clinical malignancy | 7 (35%) |
Diameter of lung tumor (mm) | |
Median (range) | 39.5 (24-81) |